If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.
Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety and tolerability of giving a new drug called ABBV-453 alone and in combination with other antimyeloma drugs to patients with relapsed or refractory multiple myeloma.
Have you been diagnosed with stage II or III triple negative breast cancer (TNBC) and have residual disease after therapy, but haven't had surgery yet? If so, you may be able to take part in a research study examining how often cancer DNA in the blood (called ctDNA) can be used to detect minimal residual disease (MRD) and early signs of cancer returning after surgery. Some participants who test positive for ctDNA but show no signs of cancer on scans may receive a study drug called Dato-DXd if they qualify.
Do you have advanced Stage III or IV Head and Neck Cancer? You might be able to join a research study. We are looking at new treatments compared to the usual care for your type of cancer.
Do you have incurable, metastatic head and neck squamous cell carcinoma ? If so, you may be able to take part in a study to see if a new drug called Cisplatin is effective.
Are you a young adult who drinks and uses social media? We are holding in-person workshops in downtown Chapel Hill to gather feedback from young adults who drink and use social media. Compensation provided.
Are you battling triple-negative breast cancer? If your cancer has come back or spread, and you haven't started treatment yet, you might qualify for a clinical trial testing a new medication. Discover more about this opportunity to find a potentially better treatment option.
Do you have acid reflux, GERD, or Barrett's Esophagus? Are you having standard of care endoscopies performed? You may be able to participate in a research study testing for Barrett's Esophagus and esophageal cancer. Compensation provided.
Have you been diagnosed with Waldenstrom Macroglobulinemia (WM) cancer? If so, you may be able to take part in a research study to determine if epcoritamab can be used to treat patients with previously treated WM.
This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.